News View All News arrow-button

Aug 16, 2018

IFM Therapeutics, LLC to Present at 256th American Chemical Society National Meeting & Exposition

BOSTON – August 16, 2018 - IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced it will present preclinical research on small-molecule approaches targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease (IBD) at the 256th National Meeting & Exposition of the 2018 American Chemical Society. The meeting is taking place in Boston, Massachusetts, from August 19-23, 2018.

The oral presentation, led by IFM Executive Vice President of Chemistry, William R. Roush, will take place on Sunday, August 19, at 10:15 AM. In his presentation, Roush will provide an overview of the role NLRP3 activation plays in inflammatory disease, as well as discuss recent advances in treatment approaches for IBD. The discussion will include the concept of using NLRP3 antagonists as single-agent therapies, as well as in combination with anti-TNF therapies.

Presentation details are as follows: 

•        Title: Small-Molecule Approaches to the Treatment of Inflammatory Bowel Disease
•        Date: August 19th, 2018
•        Presentation Time: 10:15 – 10:45 AM EDT
•        Presenter: William R. Roush, Ph.D.
•        Location: Room 210 B/C, Boston Convention & Exhibition Center

IFM, through its subsidiary IFM Tre, is developing a suite of unique small-molecule NLRP3 candidates for the treatment of serious inflammatory diseases. One of these candidates is a gut-directed NLRP3 candidate, which, in addition to potential use as a single-agent therapy for inflammatory disease, could have ideal compatibility as a combination agent with systemic immunosuppressive drug regimens to enhance efficacy without impacting patient safety. 

About IFM Therapeutics, LLC 

IFM Therapeutics, LLC (IFM) is a privately held biopharmaceutical company based in Boston, Massachusetts. The company was founded by an international group of preeminent scientists and physicians who have spent decades understanding innate immunity and the role it plays in regulating the immune system. IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, auto-immunity, and inflammatory disorders. IFM owns and operates IFM Tre, a subsidiary company launched in July of 2018 that is developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway. For more information, please visit www.ifmthera.com.     

Media Contact:
Spectrum
Andrew Bailey
abailey@spectrumscience.com 
P: (+1) 202-587-2521

Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com
P: (+1) 212-362-1200
 


 












Media Contact

Amanda Sellers
Spectrum Science Communications
404-865-3597
asellers@spectrumscience.com